HIPRA

What HIPRA does

HIPRA is a privately held Spanish biopharmaceutical company headquartered in Amer (Girona), Spain, with a 50+ year track record in vaccine research, development, production, and commercialization. The company operates under a One Health framework spanning animal health, human health, and contract development and manufacturing (CDMO). Its core business is veterinary vaccines across multiple species—poultry, swine, ruminants (cattle, sheep, goats), rabbits, fish, and companion animals—organised around disease platforms such as coccidiosis (EVANOVO, EVANT, EVALON), Gumboro/IBD (GUMBOHATCH, HIPRAGUMBORO), avian respiratory diseases (RESPIVAC aMPV, HIPRAVIAR range), swine enteric disease (VEPURED), and ruminant reproductive and mastitis pathogens (UBAC, DIVENCE, INMEVA, VIMCO). Supporting the vaccine portfolio is a proprietary Smart Vaccination ecosystem that combines RFID-tagged vaccines, dedicated delivery devices (Hipraject, Hipraspray, HIPRADERMIC needle-free injector), and the HIPRAlink digital app, alongside services including HIPRA Stats (data analytics), HIPRA Diagnos (diagnostics), HIPRA University (CPD-accredited training), and the Global Hatchery Health Programme.

The commercial model is sales-led and global, leveraging more than 40 wholly-owned subsidiaries to reach over 100 countries, supplemented by regional channel partnerships (Elanco in the U.S. poultry market, Agilis in Australia, ConcerVet in Mexico). HIPRA ranks fifth worldwide in animal health vaccines and has registered more than 20 veterinary vaccines with the European Medicines Agency over the past decade, working across more than 300 pathogens. Manufacturing scale comprises 50,000+ m² of operational facilities with 24,000L of microbial culture capacity, 2,000L of mammalian cell bioreactor capacity (expanding to 8,000L), and aseptic filling capacity of up to 90 million vials per year. In January 2025 HIPRA launched HIPRA Biotech Services, a CDMO unit providing development and manufacturing services for biological products to third-party biotech and pharmaceutical companies, with management projecting this to contribute 15-20% of group revenue in the medium term. The Human Health line includes Bimervax, a protein-based COVID-19 vaccine adapted to the LP.8.1 variant that secured a 2025 European Commission joint procurement framework contract with 14 participating member states. Revenue figures are not publicly disclosed.

Name

HIPRA

Legal name

HIPRA, S.A.

Website

https://hipra.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

HIPRA is a privately held Spanish biopharmaceutical company that ranks fifth worldwide in animal health vaccines, serving livestock producers and veterinarians across 100+ countries with a proprietary vaccine portfolio, Smart Vaccination IoT devices, and a newly launched CDMO unit for biologics manufacturing.

Ownership category

akta.pro rank

Product category

Veterinary Vaccines

NAICS

Veterinary Services (54194), Veterinary Services (541940), Support Activities for Animal Production (11521)

SIC

Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Multi-site/Corporate Group Operations Platforms (Franchise/MSO Tools, Standardization) (HLAMAGAM)

Keywords

• Veterinary vaccines
• Animal health products
• Biological contract manufacturing
• Poultry health solutions
• Livestock disease prevention

Headquarters

HQ city

Amer

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Animal Health Vaccines and Pharmaceuticals: HIPRA develops, produces, and commercializes vaccines and pharmaceutical products for animals including poultry, swine, cattle, sheep, goats, rabbits, fish, and dogs. The company ranks fifth worldwide in animal health vaccines.
2. CDMO Services (HIPRA Biotech Services): HIPRA provides development and manufacturing services for biological products and vaccines to third-party biotechnology and pharmaceutical companies. Services span from R&D activities, optimization and industrial scale-up, from early research phases through to commercial-scale manufacturing. HIPRA estimates CDMO could represent 15-20% of Group's total revenue in medium term.
3. Human Health COVID-19 Vaccine Procurement: HIPRA developed Bimervax®, a protein-based COVID-19 vaccine adapted to the LP.8.1 variant. The European Commission signed joint procurement contract for up to 4 million doses, with 14 participating countries. Contract runs for up to two years.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

HIPRA is a Spanish biopharmaceutical company that researches, produces, and commercializes veterinary vaccines and pharmaceutical products for animal health across poultry, swine, ruminants, rabbits, fish and companion animals. It also develops the human COVID-19 vaccine Bimervax®, and operates HIPRA Biotech Services, a CDMO unit offering development and manufacturing services for biological products and vaccines to third-party biotechnology and pharmaceutical companies.

Product overview

HIPRA is a biopharmaceutical company operating under a One Health approach with two main divisions: Animal Health and Human Health, plus a CDMO services unit. The Animal Health portfolio centers on vaccines across multiple species (poultry, swine, ruminants, rabbits, fish, companion animals) organized around key platforms: coccidiosis control (EVANOVO®, EVANT®, EVALON®), Gumboro/IBD prevention (GUMBOHATCH®, HIPRAGUMBORO® lines), avian respiratory diseases (RESPIVAC® aMPV, HIPRAVIAR® TRT/SHS/ILT/CLON), swine health (VEPURED®, Mhyosphere® PCV ID), and ruminant health (UBAC®, DIVENCE®, INMEVA®, VIMCO®). Supporting platforms include Smart Vaccination (Hipraject®, Hipraspray®, HIPRAlink® app with RFID technology), HIPRA Stats (data analytics), HIPRA Diagnos (diagnostics), HIPRA University (CPD training), and the Global Hatchery Health Programme. The CDMO unit offers biologics development and manufacturing services. Human Health includes Bimervax® COVID-19 vaccine. The company controls all phases from research to production and commercialization across 40+ subsidiaries serving 100+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• HIPRA Biotech Services: HIPRA's specialized CDMO unit for the development and manufacturing of biologics for third parties
• HIPRA University
• HIPRA Campus
• HIPRA LAND LAB
• UBAC
• GUMBOHATCH
• EVANOVO
• EVALON
• EVANT
• HIPRAVIAR TRT
• RESPIVAC aMPV
• INMEVA
• DIVENCE
• HIPRADERMIC
• SPEEDCELL
• HIPRA Stats
• HIPRA Diagnos
• HIPRAlink Vaccination
• Global Hatchery Health Programme

Products and services

• EVANOVO® Attenuated live vaccine against coccidiosis in broilers, specifically developed for in-ovo injection administration. Provides comprehensive immune response against Eimeria species through precocity-attenuated technology, targeting commercial poultry hatcheries and integrated broiler producers.
• EVANT® Live vaccine against avian coccidiosis in oral suspension formulation for coarse spray administration in chickens. Part of HIPRA's coccidiosis control portfolio for poultry producers.
• EVALON® Live vaccine against avian coccidiosis in oral suspension for spray application. Strategic coccidiosis control solution for poultry operations.
• GUMBOHATCH® New-generation immune complex vaccine against Infectious Bursal Disease (IBD/Gumboro). Features competitive exclusion differential and 100% IgY-coated vaccine strain for optimal balance of efficacy and safety against emerging IBDV strains, targeting commercial poultry hatcheries.
• HIPRAGUMBORO® GM97 - G97 Live vaccine against Gumboro disease using the GM97 strain, administered as oral freeze-dried tablet, targeting poultry producers managing IBD prevention programs.
• HIPRAGUMBORO® CH/80 - CW Cloned live vaccine against Gumboro disease using CH/80 strain in oral freeze-dried tablet formulation, for poultry producers requiring IBD control.
• RESPIVAC® aMPV Attenuated live vaccine against avian metapneumovirus (aMPV) subtype B with cross-protection against subtype A. Available as lyophilisate for oculonasal suspension or drinking water administration, applicable at hatchery, on farm, or during lay. Targeted at commercial poultry producers (broilers, layers, breeders) dealing with respiratory disease outbreaks.
• HIPRAVIAR® TRT Inactivated vaccine against turkey rhinotracheitis and swollen head syndrome, in injectable emulsion formulation. Provides long-term protection with same subtype, origin (chicken), and strain as the corresponding live vaccine, targeting turkey producers and breeding operations.
• HIPRAVIAR® ILT Live vaccine against Avian Infectious Laryngotracheitis strain CHP50 in oculonasal freeze-dried tablet formulation, for poultry producers managing ILT outbreaks.
• HIPRAVIAR® CLON Live vaccine against Newcastle disease using CL/79 clon strain in oral freeze-dried tablet, for poultry producers requiring ND control.
• HIPRAVIAR® SHS Live vaccine against turkey rhinotracheitis and swollen head syndrome in oculonasal freeze-dried tablet formulation, for turkey producers.
• HIPRAVIAR® AP Active immunisation vaccine for pigeons to prevent paramyxovirus infections, targeting pigeon breeders and racing pigeon operations.
• UBAC® Mastitis vaccine for ruminants targeting Streptococcus uberis. HIPRA's first ruminant vaccine registered in Australia for prevention of intramammary infections in dairy cows, addressing high disease prevalence (over 30% in major regions).
• DIVENCE® BVD (Bovine Viral Diarrhoea) control vaccine with DIVA (Differentiating Infected from Vaccinated Animals) capability. Supports BVD eradication strategies by enabling serological differentiation between vaccinated and naturally infected animals, targeting cattle producers and national eradication programs.
• INMEVA® Inactivated vaccine for prevention and control of enzootic abortion in sheep and goats caused by Chlamydia abortus. Includes protection against Salmonella Abortusovis, targeting sheep and goat producers.
• VIMCO® Inactivated vaccine against mastitis in sheep and goats, providing protection against Staphylococcus spp. Targeted at dairy sheep and goat producers for udder health management. Celebrating 10 years in market.
• VEPURED® Purified recombinant Vt2e vaccine for edema disease prevention in swine. Targets Shiga toxin-producing E. coli (STEC) infections affecting piglets, for commercial swine producers.
• Bimervax® Protein-based COVID-19 vaccine adapted to the LP.8.1 variant, developed and manufactured by HIPRA. First Spanish COVID-19 vaccine fully developed and produced in Spain and Europe. Received Marketing Authorization from the European Commission. Targeted at EU member state governments for pandemic preparedness procurement.
• HIPRADERMIC® Next-generation needle-free intradermal vaccine administration device using high-pressure technology. Delivers vaccines directly into the dermal layer ensuring robust immune response while eliminating iatrogenic cross-contamination risk, targeting poultry vaccination programs and veterinary practitioners.
• HIPRA Biotech Services (CDMO) Contract Development and Manufacturing Organization (CDMO) services for biological products and vaccines. Services span R&D activities, optimization and industrial scale-up, from early research phases through to commercial-scale manufacturing. Facilities include 24,000L microbial culture capacity, 2,000L (expanding to 8,000L) mammalian cell bioreactor capacity, and 90 million vials/year aseptic filling capacity. Targeted at biotechnology and pharmaceutical companies seeking biologics manufacturing capacity.

Quantifiable outcome

• HIPRA ranks 5th worldwide in animal health vaccines
• +6 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• European CommissioncoreStrategic or Co-development Partner · 3 October 2025European Commission signed joint procurement framework contract with HIPRA for up to 4 million doses of Bimervax®, a protein-based COVID-19 vaccine adapted to the LP.8.1 variant. 14 participating countries can order doses without minimum requirements. Contract runs for up to two years. The agreement strengthens EU strategic autonomy by ensuring all R&D, production, and fill-and-finish operations are located in Europe.
• Agilis (Australia)coreChannel Partner/ Reseller/ Distributor · 1 April 2025HIPRA partnered with local partner Agilis in Australia for the launch of UBAC®, HIPRA's first ruminant vaccine registered in Australia. Agilis helped conduct a targeted roadshow across Victoria with in-person sessions in Camperdown and Warragul, plus online session for Tasmania, engaging large-practice vets overseeing thousands of dairy cows.
• Elanco Animal HealthcoreChannel Partner/ Reseller/ Distributor · 1 January 2025HIPRA and Elanco Animal Health partnered to bring two avian metapneumovirus (aMPV) vaccines (RESPIVAC® aMPV and HIPRAVIAR® TRT) to the U.S. poultry market. Elanco provides market access, field support, and ensures consistent supply for U.S. producers dealing with this costly respiratory disease affecting 60-80% of commercial turkey flocks. Field trials showed significant improvement among vaccinated birds compared to the previous year.
• European Biotechnology CompanycoreStrategic or Co-development Partner · 1 January 2025HIPRA Biotech Services secured its first contract for the supply of a biological product for clinical studies with a European biotechnology company, just 9 months after launch. The CDMO unit is in advanced negotiation stages for several additional projects. This partnership validates HIPRA's differentiated value proposition based on top-tier scientific, technical, and industrial capabilities.
• ConcerVet (Mexico)minorStrategic or Co-development Partner · 1 January 2025HIPRA MEXICO collaborated with the National Council for Certification in Veterinary Medicine and Zootechnics (ConcerVet) to deliver the Diploma Program in Bovine Health: Prevention and Eradication of IBR and BVD. The six-module, accredited program brought together over 180 participants from Mexico and Latin America with national and international specialists.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Zoetis: Zoetis is the world's largest animal health company, offering vaccines, diagnostics, and pharmaceuticals across livestock and companion animals. Directly competes with HIPRA in the livestock vaccine segment and represents the dominant incumbent HIPRA must outflank with regional specialization and the One Health positioning.
• Boehringer Ingelheim Animal Health: Boehringer Ingelheim's animal health division is a top-three global player in veterinary vaccines and therapeutics. It competes with HIPRA in poultry, swine and ruminant vaccines and shares the strategic CDMO/biologics manufacturing footprint overlap.
• Merck Animal Health (MSD): MSD Animal Health is a global leader in livestock and companion animal vaccines and pharmaceuticals. It competes head-to-head with HIPRA in poultry and swine vaccines and represents one of the few competitors with comparable biologics R&D and global commercial scale.

Direct peers

• Elanco Animal Health: Elanco is a top-five global animal health company and a direct competitor in poultry and livestock vaccines, while also being a current distribution partner of HIPRA for the U.S. market (aMPV vaccines). The dual relationship highlights Elanco as both a comparable peer and a strategic channel for HIPRA's U.S. expansion.
• Ceva Santé Animale: Ceva is a global veterinary pharmaceutical company specializing in vaccines and pharmaceuticals for poultry, swine, and ruminants. It is one of the closest direct competitors to HIPRA in livestock vaccines, particularly in emerging markets and poultry segments.
• Virbac: Virbac is a global animal health company focused on vaccines, pharmaceuticals, and diagnostics for livestock and companion animals. Comparable in scale and product mix to HIPRA's animal health portfolio, with particular overlap in ruminant and poultry therapeutics.
• Vetoquinol: Vetoquinol is a mid-sized global animal health pharmaceutical company offering vaccines and therapeutic products for livestock and companion animals. Similar in scale and geographic reach to HIPRA, competing across multiple species segments.
• Phibro Animal Health: Phibro is a global animal health and nutrition company providing vaccines, pharmaceuticals, and feed additives for livestock. Comparable to HIPRA in livestock-focused product mix and mid-cap scale, with overlap in poultry and cattle segments.

Emerging players

• IDT Biologika: IDT Biologika is a veterinary vaccine and biopharmaceutical CDMO specialist with capabilities in vaccine development and manufacturing. Highly comparable to HIPRA Biotech Services in the CDMO segment and a direct veterinary vaccines competitor in selected species.

Regional players

• Bioveta: Bioveta is a Central European veterinary vaccines and pharmaceuticals company with strong regional presence. Comparable in product mix and mid-cap scale to HIPRA, primarily operating across Central and Eastern Europe rather than competing directly in HIPRA's priority Western/U.S. markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCrtF9rpXG8-boyeZJiqQrEw
• LinkedInlinkedin.com/company/hipra

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HIPRA